Contrast-Induced Nephropathy: The Wheel Has Turned 360 Degrees

References

• Aspelin, P, Aubry, P, Fransson, S-G, Strasser, R, Willenbrock, R, Berg, KJ, for the NEPHRIC Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491–9.
   PubMed Web of Science ®Google Scholar
• Solomon R, Natarajan M, Doucet S, Harma SK, Staniloae CS, Katholi JL, et al. The cardiac-angiography in renally impaired patients (CARE) study: a randomized, double blind trial of contrast-induced nephropathy (CIN) in high risk patients. Circulation 2007; 115: 3189–96
   PubMed Web of Science ®Google Scholar
• Barrett BJ, Katzberg RW, Thomsen HS, Chen N, Sahani D, Soulez G, et al. Contrast induced nephropathy in patients with chronic kidney disease undergoing computed tomography. A double blind comparison of iodixanol and iopamidol. Invest Radiol 2006; 41: 815–21
   PubMed Web of Science ®Google Scholar
• Thomsen, HS, Morcos, SK, Erley, CM, Grazioli, L, Bonomo, L, Ni, Zhaohui, et al. The ACTIVE trial: comparison of the effects on renal function of iomeprol-4000 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol 2008; 43: 170–8.
   PubMed Web of Science ®Google Scholar
• Hardiek, KJ, Katholi, RE, Robbs, RS, Katholi, CE. Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography. J Diabet Complications 2008; in press.
   Google Scholar
• Liss P, Persson PB, Hansell P, Lagerqvist B. Renal failure in 57,925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media. Kidney Int 2006; 10: 1811–7
   Google Scholar
• Thomsen HS, Morcos SK. Contrast-medium-induced nephropathy: is there a new consensus? A review of published guidelines. Eur Radiol 2006; 16: 1835–40
   Google Scholar
• Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol 2003; 76: 513–8
   PubMed Web of Science ®Google Scholar
• Hou SH, Bushinsky DA, Wish JB, Cohan JJ, Harrington JT. Hospital acquired renal insufficiency: a prospective study. Am J Med 1993; 74: 243–8
   Google Scholar
• Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39: 930–6
   PubMed Web of Science ®Google Scholar
• Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kant KM, et al. The prognostic implications of further renal function deterioration with 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000; 36: 1542–8
   PubMed Web of Science ®Google Scholar
• McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Niel WW. Acute renal failure after coronary intervention: incidence, risk factors and relationship to mortality. Am J Med 1997; 103: 368–75
   PubMed Web of Science ®Google Scholar
• Morcos, SK, Thomsen, HS, Webb, JAW, and, members of the Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR). Contrast media induced nephrotoxicity: a consensus report. Eur Radiol 1999;9:1602–13.
   PubMed Web of Science ®Google Scholar
• Gutierrez N, Diaz A, Timmis GC. Determinants of serum creatinine trajectory in acute contrast nephropathy. J Intervent Cardiol 2002; 15: 349–54
   Google Scholar
• Waybill MM, Waybill PN. Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. J Vasc Interv Radiol 2001; 12: 3–9
   PubMed Web of Science ®Google Scholar
• Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analyses. JAMA 1996; 275: 1489–94
   PubMed Web of Science ®Google Scholar
• Finn WF. The clinical and renal consequences of contrast-induced nephropathy. Nephrol Dial Transplant 2006; 21(Suppl 1)i2–10
   Google Scholar
• Meschi M, Detrenis S, Musini S, Strada E, Savazzi G. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy. Crit Care Med 2006; 34: 2060–8
   PubMed Web of Science ®Google Scholar
• Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy. A clinical and evidence based approach. Circulation 2006; 113: 1799–806
   PubMed Web of Science ®Google Scholar
• Pannu, N, Wiebe, N, Tonelli, M, for the Alberta Kidney Disease Network. Prophylaxis strategies for contrast-induced nephropathy. JAMA 2006;295:2765–79.
   PubMed Web of Science ®Google Scholar
• Toprak O, Citrit M. Risk factors and therapy strategies for contrast induced nephropathy. Renal Failure 2006; 28: 365–81
   PubMed Web of Science ®Google Scholar
• Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ 2005; 172: 1461–71
   PubMed Web of Science ®Google Scholar
• Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology and patients at risk. Kidnet Int 2006; 69: S11–5
   Google Scholar
• Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259–64
   PubMed Web of Science ®Google Scholar
• Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older: a prospective study. Arch Intern Med 1990; 150: 1237–42
   PubMedGoogle Scholar
• Bettmann MA. Contrast medium induced nephropathy: critical review of the existing clinical evidence. Nephrol Dial Transplant 2005; 20 Suppl 1: i12–7
   Google Scholar
• Sharma SK, Kini A. Effect of non-ionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insufficiency: pooled analysis of the randomized trials. Catheter Cardiovasc Interv 2005; 65: 386–93
   Google Scholar
• Solomon R, DuMouchel W. Contrast media and nephropathy. Findings from systematic analysis and Food and Drug Administration reports of adverse effects. Invest Radiol 2006; 41: 651–60
   PubMed Web of Science ®Google Scholar
• Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 2005; 68: 2256–63
   PubMed Web of Science ®Google Scholar
• Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196: a randomized trial. Kidney Int 1995; 47: 254–61
   PubMed Web of Science ®Google Scholar
• Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. N Engl J Med 2006; 354: 379–86
   PubMed Web of Science ®Google Scholar
• Katzberg R, Barrett B. Risk of contrast-induced nephropathy with the intravenous administration of iodinated contrast media. Radiology 2007; 243: 622–8
   PubMed Web of Science ®Google Scholar
• Thomsen, HS, Morcos, SK, and, members of the Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). In which patients should serum-creatinine be measured before contrast medium administration?. Eur Radiol 2005;15:749–56.
   Web of Science ®Google Scholar
• McCarty CS, Becker JA. Multiple myeloma and contrast media. Radiology 1992; 183: 519–21
   Google Scholar
• Thomsen HS. Reducing the risk of contrast medium induced nephropathy. Contrast media. Safety issues and ESUR guidelines, HS Thomsen. Springer Verlag, Heidelberg 2006; 35–45
   Google Scholar
• Choyke PL, Cady K, DePollar SL, Austin H. Determination of serum creatinine prior to iodinated contrast media: is it needed in all patients?. Tech Urol 1998; 4: 65–9
   PubMedGoogle Scholar
• Olsen JC, Salomon B. Utility of the creatinine prior to intravenous contrast studies in the emergency department. J Emerg Med 1996; 14: 543–6
   Google Scholar
• Tippins RB, Torres WE, Baumgartner BR, Baumgarten DA. Are screening serum creatinine levels necessary prior to outpatient CT examinations?. Radiology 2000; 216: 481–4
   PubMedGoogle Scholar
• Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–70
   PubMed Web of Science ®Google Scholar
• Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002; 13: 2140–4
   PubMed Web of Science ®Google Scholar
• Blaufox MD, Aurell M, Bubeck B, Fommei E, Piepsz A, Russell C, et al. Report of the Radionuclide in Nephrourology Committee on renal clearance. J Nucl Med 1996; 37: 1883–90
   PubMed Web of Science ®Google Scholar
• Detrenis S, Meschi M, Bertolini L, Savazzi G. Contrast medium administration in the elderly patient: is advancing age an independent risk factor for contrast nephropathy after angiographic procedures. J Vasc Interv Radiol 2007; 18: 277–85
   Google Scholar
• Drarnidharka VR, Kwon C, Stevens C. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221–6
   Google Scholar
• Hoffmann U, Fichereder M, Kruger B, Drobnik W, Kramer BK. The value of N-acetylcystine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004; 15: 407–10
   PubMed Web of Science ®Google Scholar
• Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188: 171–8
   PubMed Web of Science ®Google Scholar
• Jo S-H, Youn T-J, Koo B-K, Parl JS, Kang HJ, Cho YS, et al. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabric (ioxaglate) in patients with renal insufficiency undergoing coronary angiography. The RECOVER study: a randomized controlled trial. J Am Coll Cardiol 2006; 48: 924–30
   PubMed Web of Science ®Google Scholar
• Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999; 72: 701–3
   PubMed Web of Science ®Google Scholar
• Briguori C, Colombo A, Airoldi F, Mirici N, Sangiorgi GM, Violante A, et al. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int 2006; 68: 2250–5
   Google Scholar
• Carraro M, Malalan F, Antonione R, Stacul F, Cova M, Petz S, et al. Effects of a dimeric vs. a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Eur Radiol 1998; 8: 144–7
   PubMedGoogle Scholar
• Kolehmainen H, Soiva M. Comparison of Xenetix 300 and Visipaque 320 in patients with renal failure. Eur Radiol 2003; 13: B32–3
   Google Scholar
• Bader BD, Berger ED, Heede MB, Silberbauer L, Duda S, Risler T, et al. What is the best hydration regimen to prevent contrast induced nephrotoxicity?. Clin Nephrol 2004; 62: 1–7
   PubMed Web of Science ®Google Scholar
• Mueller C, Burkle G, Buettner HS, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media associated nephropathy. Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162: 329–36
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: preparation for angiography in renal dysfunction – a randomized trial of inpatient vs outpatient hydration protocols for cardiac catherization in mild-to-moderate renal dysfunction. Chest 1998; 114: 1570–4
   PubMed Web of Science ®Google Scholar
• Trivedi HS, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P, Hewett J. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Prac 2003; 93: C29–4
   PubMed Web of Science ®Google Scholar
• Krasuski RA, Beard BM, Geoghagan JD, Thompson CM, Guidera SA. Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol 2003; 15: 699–702
   PubMedGoogle Scholar
• Dussol B, Morange S, Loundoun A, Auquier P, Berland Y. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 2006; 21: 2120–6
   PubMed Web of Science ®Google Scholar
• Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291: 2328–34
   PubMed Web of Science ®Google Scholar
• Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, et al. Renal insufficiency following contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 2007; 115: 1211–7
   PubMed Web of Science ®Google Scholar
• Recio-Mayoral A, Chaparro M, Prado B, Cozar R, Mendez I, Naerjee D, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acteylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO study. J Am Coll Cardiol 2007; 49: 1283–8
   PubMed Web of Science ®Google Scholar
• Clavijo LC, Pinto TL, Kuchulakanti PK, Torguson R, Chu WW, Satler LF, et al. Effect of a rapid intra-arterial infusion of dextrose 5% prior to coronary angiography on frequency of contrast-induced nephropathy in high-risk patients. Am J Cardiol 2006; 97: 981–3
   PubMed Web of Science ®Google Scholar
• Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331: 1416–20
   PubMed Web of Science ®Google Scholar
• Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992; 62: 413–5
   PubMed Web of Science ®Google Scholar
• Bakris GL, Lass N, Gabaer AO, Jones JD, Burnette JCJr. Radiocontrast medium induced declines in renal function. A role for oxygen free radicals. Am J Physiol 1990; 175: 57–60
   Google Scholar
• Atkins JL. Effect of sodium bicarbonate preloading on ischemic renal failure. Nephron 1986; 44: 70–6
   PubMedGoogle Scholar
• Morcos SK. Prevention of contrast media-induced nephrotoxicity after angiographic procedures. J Vasc Interv Radiol 2005; 16: 13–23
   Google Scholar
• Fishbane S, Durham JH, Marzo, Rudnick M. N-acetylcysteine in the prevention of radiocontrast induced nephropathy. J Am Soc Nephrol 2004; 15: 251–60
   PubMed Web of Science ®Google Scholar
• Tepel M, van der Giet M, Schwartzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180–4
   PubMed Web of Science ®Google Scholar
• Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo Elia P, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent-associated nephrotoxicity. Eur Heart J 2004; 25: 206–11
   PubMed Web of Science ®Google Scholar
• Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006; 354: 2773–82
   PubMed Web of Science ®Google Scholar
• Liu R, Nair D, Ix J, Moore DH, Bent S. N-acetylcysteine for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. J Gen Intern Med 2005; 20: 193–200
   PubMed Web of Science ®Google Scholar
• Zagler A, Azadpour M, Mercado C, Hennekens CH. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trial. Am Heart J 2006; 151: 140–5
   Google Scholar
• Kshirsagar AV, Poole C, Mottl A, Shohan D, Franceschini N, Tudor G, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 2004; 15: 761–9
   PubMed Web of Science ®Google Scholar
• Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast induced nephropathy after intravascular angiography; a systemic review and meta-analysis. BMC Med 2004; 2: 38
   PubMed Web of Science ®Google Scholar
• Vaitkus PT, Brar C. N-acetylcysteine in the prevention of contrast induced nephropathy: publication bias perpetuated by meta-analyses. Am Heart J 2007; 153: 275–80
   Google Scholar
• Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy. Arch Intern Med 2006; 166: 161–6
   PubMed Web of Science ®Google Scholar
• Biondi-Zoccai GG, Lotrionte M, Abbate A, Testa L, Remigi E, Burzotta F, et al. Compliance with QUOROM and quality of reporting over overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. Br Med J 2006; 332: 202–9
   PubMed Web of Science ®Google Scholar
• Curhan GC. Prevention of contrast nephropathy. JAMA 2003; 289: 606–8
   Google Scholar
• Poletti PA, Saudan P, Platon A, Mermillod B, Sautter AM, Vermeulen B, et al. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol 2007; 189: 687–92
   PubMed Web of Science ®Google Scholar
• Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004; 110: 2837–42
   PubMed Web of Science ®Google Scholar
• Ix JH, McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant 2004; 19: 2747–53
   PubMed Web of Science ®Google Scholar
• Bagshaw SM, Ghali WM. Theophylline for prevention of radiocontrast nephropathy: a systemic review and meta-analysis. Arch Intern Med 2005; 165: 1087–93
   PubMed Web of Science ®Google Scholar
• Stevens MA, McCullough PA, Tobin KJ, Speck JP, Westveer DC, Guido-Allen DA, et al. A prospective randomized trial for prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. study. J Am Coll Cardiol 1999; 33: 403–11
   PubMed Web of Science ®Google Scholar
• Gare M, Haviv YS, Ben-Yehuda A, Rubinger D, Bdolah-Abram T, Fuchs S, et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 1999; 34: 1682–8
   PubMed Web of Science ®Google Scholar
• Hans SS, Hans BA, Dhillon R, Dmuchowski C, Glover J. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am Surg 1998; 64: 432–6
   PubMed Web of Science ®Google Scholar
• Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994; 45: 259–65
   PubMed Web of Science ®Google Scholar
• Abizaid AS, Clark CE, Mintz GS, Dosa S, Popma JJ, Pichard AD, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999; 83: 260–3
   PubMed Web of Science ®Google Scholar
• Arici M, Usalan C, Altun B, Erdem Y, Yasavul U, Turgan C, et al. Radiocontrast-induced nephropathy and urinay alphagluthione S-transferase levels: effect of amlopidine administration. Int Urol Nephrol 2003; 35: 255–61
   PubMedGoogle Scholar
• Carraro M, Mancini W, Artero M, Stacul F, Grotto M, Cova M, Faccini L. Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. Nephrol Dial Transplant 1996; 11: 444–8
   Google Scholar
• Khoury Z, Schlicht JR, Como J, Karschner JK, Shapiro AP, Mook WJ, et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy 1995; 15: 59–65
   PubMed Web of Science ®Google Scholar
• Koch JA, Plum J, Grabensee B, Modder U. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radicontrast media? PGE1 study Group. Nephrol Dial Transplant 2000; 15: 43–9
   PubMed Web of Science ®Google Scholar
• Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 1999; 51: 521–36
   PubMedGoogle Scholar
• Toprak O, Cirit M, Mayata S, Yesil M, Aslan LS. The effect of pre-procedural captopril on contrast media induced nephropathy who underwent coronary angiography. Anadolu Kardiyol Derg 2003; 3: 98–103
   PubMedGoogle Scholar
• Toprak O. Angiotension converting emzymes inhibitors and contrast-induced nephropathy. Renal Failure 2006; 28: 99–100
   PubMed Web of Science ®Google Scholar
• Morcos SK. Dialysis and contrast media. Contrast media: safety issues and ESUR guidelines, HS Thomsen. Springer Verlag, Heidelberg 2006; 47–52
   Google Scholar
• Deray G. Dialysis and iodinated contrast media. Kidney Int 2006; 69: S25–9
   Web of Science ®Google Scholar
• Vogt B, Ferrari P, Schönholzer C, Marti HP, Mohaupt M, Wiederkehr M, et al. Pre-emptive haemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001; 111: 692–8
   PubMedGoogle Scholar
• Frank H, Werner D, Lorusso V, Klinghammer L, Daniel WG, Kunzendorf U, et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol 2003; 60: 176–82
   PubMedGoogle Scholar
• Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349: 1333–40
   PubMed Web of Science ®Google Scholar
• Marenzi G, Lauri G, Campodonico J, Marana I, Assanelli E, De Metrio M, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 2006; 119: 155–62
   PubMed Web of Science ®Google Scholar
• Sam AD II, Morasch MD, Collins J, Song G, Chen R, Pereles FS. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 2003; 38: 313–8
   PubMed Web of Science ®Google Scholar
• Thomsen HS. Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol 2004; 14: 1654–6
   PubMedGoogle Scholar
• Akgun H, Gonlusen G, Cartwright J, Suki WN, Truong LD. Are gadolinium based contrast media nephrotoxic? A renal biopsy study. Arch Pathol Lab Med 2006; 130: 1354–7
   PubMedGoogle Scholar
• Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 2007; 7: 130–7
   PubMedGoogle Scholar
• Thomsen HS. Non-insulin dependent diabetes and contrast media. Contrast media: safety issues and ESUR guidelines, HS Thomsen. Springer Verlag, Heidelberg 2006; 35–46
   Google Scholar
• Thomsen, HS, Morcos, SK, and, members of Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR). Contrast media and metformin. Guidelines to diminish the risk of lactic acidosis in non-insulin dependent diabetics after administration of contrast media. Eur Radiol 1999;9:738–40.
   PubMed Web of Science ®Google Scholar
• Webb, JAW, Stacul, F, Thomsen, HS, Morcos, SK, and Members of the Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR). Late adverse reactions to intravascular iodinated contrast media. Eur Radiol 2003;13:181–4.
   PubMed Web of Science ®Google Scholar